Literature DB >> 26857560

Clarification on the impact of cervarix vaccination on human papillomavirus infection and cervical cancer in the United Kingdom.

Darron Brown1, Amit Sharad Kulkarni2, Matt Pillsbury2, Alain Luxembourg2, Alfred Saah2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26857560      PMCID： PMC4964804          DOI： 10.1080/21645515.2016.1143159

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


× No keyword cloud information.
  8 in total

1.  Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

Authors:  Matti Lehtinen; Jorma Paavonen; Cosette M Wheeler; Unnop Jaisamrarn; Suzanne M Garland; Xavier Castellsagué; S Rachel Skinner; Dan Apter; Paulo Naud; Jorge Salmerón; Song-Nan Chow; Henry Kitchener; Júlio C Teixeira; James Hedrick; Genara Limson; Anne Szarewski; Barbara Romanowski; Fred Y Aoki; Tino F Schwarz; Willy A J Poppe; Newton S De Carvalho; Maria Julieta V Germar; Klaus Peters; Adrian Mindel; Philippe De Sutter; F Xavier Bosch; Marie-Pierre David; Dominique Descamps; Frank Struyf; Gary Dubin
Journal:  Lancet Oncol       Date:  2011-11-08       Impact factor: 41.316

2.  Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

Authors:  Cosette M Wheeler; Xavier Castellsagué; Suzanne M Garland; Anne Szarewski; Jorma Paavonen; Paulo Naud; Jorge Salmerón; Song-Nan Chow; Dan Apter; Henry Kitchener; Júlio C Teixeira; S Rachel Skinner; Unnop Jaisamrarn; Genara Limson; Barbara Romanowski; Fred Y Aoki; Tino F Schwarz; Willy A J Poppe; F Xavier Bosch; Diane M Harper; Warner Huh; Karin Hardt; Toufik Zahaf; Dominique Descamps; Frank Struyf; Gary Dubin; Matti Lehtinen
Journal:  Lancet Oncol       Date:  2011-11-08       Impact factor: 41.316

3.  Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.

Authors:  Aimée R Kreimer; Frank Struyf; Maria Rowena Del Rosario-Raymundo; Allan Hildesheim; S Rachel Skinner; Sholom Wacholder; Suzanne M Garland; Rolando Herrero; Marie-Pierre David; Cosette M Wheeler; Paula González; Silvia Jiménez; Douglas R Lowy; Ligia A Pinto; Caroline Porras; Ana Cecilia Rodriguez; Mahboobeh Safaeian; Mark Schiffman; John T Schiller; John Schussler; Mark E Sherman; F Xavier Bosch; Xavier Castellsague; Archana Chatterjee; Song-Nan Chow; Dominique Descamps; Francisco Diaz-Mitoma; Gary Dubin; Maria Julieta Germar; Diane M Harper; David J M Lewis; Genara Limson; Paulo Naud; Klaus Peters; Willy A J Poppe; Brian Ramjattan; Barbara Romanowski; Jorge Salmeron; Tino F Schwarz; Julio C Teixeira; Wiebren A A Tjalma
Journal:  Lancet Oncol       Date:  2015-06-09       Impact factor: 41.316

4.  Impact of vaccinating boys and men against HPV in the United States.

Authors:  Elamin H Elbasha; Erik J Dasbach
Journal:  Vaccine       Date:  2010-08-14       Impact factor: 3.641

Review 5.  Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis.

Authors:  Talía Malagón; Mélanie Drolet; Marie-Claude Boily; Eduardo L Franco; Mark Jit; Jacques Brisson; Marc Brisson
Journal:  Lancet Infect Dis       Date:  2012-08-22       Impact factor: 25.071

6.  Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.

Authors:  J Paavonen; P Naud; J Salmerón; C M Wheeler; S-N Chow; D Apter; H Kitchener; X Castellsague; J C Teixeira; S R Skinner; J Hedrick; U Jaisamrarn; G Limson; S Garland; A Szarewski; B Romanowski; F Y Aoki; T F Schwarz; W A J Poppe; F X Bosch; D Jenkins; K Hardt; T Zahaf; D Descamps; F Struyf; M Lehtinen; G Dubin
Journal:  Lancet       Date:  2009-07-06       Impact factor: 79.321

7.  Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination.

Authors:  Paulo S Naud; Cecilia M Roteli-Martins; Newton S De Carvalho; Julio C Teixeira; Paola C de Borba; Nervo Sanchez; Toufik Zahaf; Gregory Catteau; Brecht Geeraerts; Dominique Descamps
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

8.  Projected impact of Cervarix™ vaccination on oncogenic human papillomavirus infection and cervical cancer in the United Kingdom.

Authors:  Thierry P Van Effelterre; Cosmina Hogea; Sylvia M Taylor
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452
  8 in total
  1 in total

Review 1.  Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus.

Authors:  Maryam Dadar; Sandip Chakraborty; Kuldeep Dhama; Minakshi Prasad; Rekha Khandia; Sameer Hassan; Ashok Munjal; Ruchi Tiwari; Kumaragurubaran Karthik; Deepak Kumar; Hafiz M N Iqbal; Wanpen Chaicumpa
Journal:  Front Immunol       Date:  2018-11-12       Impact factor: 7.561
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.